<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1796</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>masterthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-08-28</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-08-21</thesisDateAccepted>
    <title language="eng">The Use of Pig insulin and Grafts in the treatment of Human Diabetes</title>
    <abstract language="eng">Biological resources are entities of natural origin with sources from either plants or animals that render a broad number of services to mankind. Purified pig insulin, pancreas, islet, and beta cells are biological resources synthesized, extracted, and isolated from pigs to provide medical services like treating human diabetes. &#13;
The observed methodology was obtained by systematically reviewing and comparing other similar scientific studies to determine the challenges and risks associated with using pig grafts (islet, pancreas, beta cells) for the treatment of type 1 diabetes (T1D), the optimal pig age for extracting graft for treatment of diabetes, differences between human and pig insulin, and the clinical trials and adoption pig insulin and graft therapies for type 1 diabetes treatment.&#13;
Xenotransplantation of pig grafts has successfully restored normoglycemia in a Type 1 diabetes patient for about 9.5 years, thus potentially being an alternative therapy to human islet allotransplantation. However, the clinical adoption of using &#13;
pig grafts for diabetes treatment is hindered by the unavailability of T1D volunteers to be used for clinical trials because of risks like zoonosis, loss of body weight, immunosuppression, and death of the transplanted pig implant.&#13;
Xenotransplantation of pig grafts to T1D can be clinically accepted through advanced practices like Genetic modifications of the pig, encapsulating the pig grafts before transplantation, and co-transplantation of the pig grafts with Mesenchymal Stem Cell (MSCs) and/or Sertoli cells (SCs). The clinical adoption of pig grafts for T1D treatment will mitigate the problem of limited islet/pancreas &#13;
donor sources encountered in allotransplantation, hence more research and studies are needed for this milestone to be accomplished.</abstract>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC0 1.0 Universell - Gemeinfreiheit (Public Domain)</licence>
    <author>Somtoo Dominic Okolie</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
  </doc>
</export-example>
